Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1/2 study has the primary objective of decitabine-primed tandem
CART 19/20 in patients with B-NHL who were confirmed as r/r B cell Non-Hodgkin's Lymphoma. A
total of 19 to 33 patients are planned to be enrolled and receive decitabine-primed tandem
CART 19/20 cell infusion. Phase 1 (9 to 18 cases) is dose escalation part, and phase 2 (10 to
15 cases) is expansion cohort part.